{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cytarabine+or+Supportive+Care", "query": { "intervention": "Cytarabine or Supportive Care" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 15, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cytarabine+or+Supportive+Care&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-26T13:37:35.935Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01147939", "title": "Study of Elacytarabine Versus Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia (AML)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Myeloid Leukemia (AML)" ], "interventions": [ { "name": "Elacytarabine", "type": "DRUG" }, { "name": "Investigator's Choice", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Clavis Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 381, "start_date": "2010-06", "completion_date": "2013-06", "has_results": false, "last_update_posted_date": "2013-09-27", "last_synced_at": "2026-09-26T13:37:35.935Z", "location_count": 23, "location_summary": "La Jolla, California • Los Angeles, California • Denver, Colorado + 16 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01147939" }, { "nct_id": "NCT00260832", "title": "Trial of Decitabine in Patients With Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Cytarabine or Supportive Care", "type": "DRUG" }, { "name": "Dacogen (decitabine) only", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eisai Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "ALL", "summary": "65 Years and older" }, "enrollment_count": 485, "start_date": "2005-11", "completion_date": "2010-12", "has_results": true, "last_update_posted_date": "2019-09-11", "last_synced_at": "2026-09-26T13:37:35.935Z", "location_count": 37, "location_summary": "Los Angeles, California • Fort Myers, Florida • Gainesville, Florida + 34 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Lakeland", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00260832" }, { "nct_id": "NCT03446638", "title": "iCare 2: Personalized Genomic Mutation Informed Treatment of Patients With Myelodysplastic Syndromes", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Myelodysplastic Syndromes" ], "interventions": [ { "name": "FDA-approved drug or combination of drugs", "type": "DRUG" }, { "name": "FLAG induction", "type": "DRUG" }, { "name": "7 + 3 induction", "type": "DRUG" }, { "name": "Low-dose cytarabine", "type": "DRUG" }, { "name": "Supportive care alone", "type": "OTHER" }, { "name": "Computational biology simulations software", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "OTHER", "DEVICE" ], "sponsor": "University of Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 0, "start_date": "2019-05", "completion_date": "2022-09", "has_results": false, "last_update_posted_date": "2019-06-11", "last_synced_at": "2026-09-26T13:37:35.935Z", "location_count": 1, "location_summary": "Gainesville, Florida", "locations": [ { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03446638" }, { "nct_id": "NCT01661881", "title": "Rituximab/Bendamustine + Rituximab/Cytarabine for Mantle Cell Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Mantle Cell Lymphoma" ], "interventions": [ { "name": "Rituximab", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Christine Ryan", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "69 Years", "sex": "ALL", "summary": "18 Years to 69 Years" }, "enrollment_count": 23, "start_date": "2012-08-16", "completion_date": "2030-04", "has_results": true, "last_update_posted_date": "2026-06-08", "last_synced_at": "2026-09-26T13:37:35.935Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01661881" }, { "nct_id": "NCT02756962", "title": "Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Cytarabine", "type": "DRUG" }, { "name": "Allogeneic stem cell transplant", "type": "PROCEDURE" }, { "name": "Bone marrow aspiration", "type": "PROCEDURE" }, { "name": "Punch skin biopsy", "type": "PROCEDURE" }, { "name": "ClinSeq", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "PROCEDURE", "DEVICE" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 107, "start_date": "2016-07-06", "completion_date": "2029-07-31", "has_results": false, "last_update_posted_date": "2025-10-28", "last_synced_at": "2026-09-26T13:37:35.935Z", "location_count": 3, "location_summary": "Gainesville, Florida • St Louis, Missouri • Rochester, New York", "locations": [ { "city": "Gainesville", "state": "Florida" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02756962" }, { "nct_id": "NCT02130869", "title": "A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neuroblastoma", "Lymphoma", "High-risk Tumor" ], "interventions": [ { "name": "CD133+ selected autologous stem cell infusion", "type": "BIOLOGICAL" }, { "name": "IL-2", "type": "BIOLOGICAL" }, { "name": "hu14.18K322A", "type": "BIOLOGICAL" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "GM-CSF", "type": "BIOLOGICAL" }, { "name": "Bendamustine", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Haploidentical natural killer cell infusion", "type": "DEVICE" }, { "name": "G-CSF", "type": "BIOLOGICAL" }, { "name": "Etoposide phosphate", "type": "DRUG" }, { "name": "CliniMACS", "type": "DEVICE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "DEVICE" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 8, "start_date": "2014-10-10", "completion_date": "2017-12-20", "has_results": false, "last_update_posted_date": "2017-12-22", "last_synced_at": "2026-09-26T13:37:35.935Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02130869" }, { "nct_id": "NCT06895473", "title": "Intrathecal Cytarabine, Methotrexate, and Hydrocortisone for the Prevention of High-Grade Chimeric Antigen Receptor T-Cell-Associated Neurotoxicity Syndrome", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hematopoietic and Lymphatic System Neoplasm" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Lumbar Puncture", "type": "PROCEDURE" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Therapeutic Hydrocortisone", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2025-06-04", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-06-26", "last_synced_at": "2026-09-26T13:37:35.935Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT06895473" }, { "nct_id": "NCT01074047", "title": "Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Azacitidine", "type": "DRUG" }, { "name": "Conventional Care Regimen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "ALL", "summary": "65 Years and older" }, "enrollment_count": 488, "start_date": "2010-06-01", "completion_date": "2016-07-25", "has_results": true, "last_update_posted_date": "2017-08-29", "last_synced_at": "2026-09-26T13:37:35.935Z", "location_count": 2, "location_summary": "Boston, Massachusetts • Houston, Texas", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01074047" }, { "nct_id": "NCT02920008", "title": "Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "guadecitabine", "type": "DRUG" }, { "name": "Treatment Choice (TC)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astex Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 302, "start_date": "2017-03-16", "completion_date": "2020-06-01", "has_results": true, "last_update_posted_date": "2024-08-28", "last_synced_at": "2026-09-26T13:37:35.935Z", "location_count": 15, "location_summary": "Los Angeles, California • Chicago, Illinois • Indianapolis, Indiana + 11 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Albuquerque", "state": "New Mexico" } ], "official_url": "https://clinicaltrials.gov/study/NCT02920008" }, { "nct_id": "NCT01701323", "title": "Expanded Cord Blood Cell Infusion Following Combination Chemotherapy in Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Leukemia of Ambiguous Lineage", "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Ex-Vivo Expanded Cord Blood Progenitor Cell Infusion", "type": "BIOLOGICAL" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Filgrastim", "type": "DRUG" }, { "name": "Fludarabine Phosphate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Nohla Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "30 Years", "sex": "ALL", "summary": "6 Months to 30 Years" }, "enrollment_count": 7, "start_date": "2012-12-10", "completion_date": "2018-05-10", "has_results": false, "last_update_posted_date": "2019-03-01", "last_synced_at": "2026-09-26T13:37:35.935Z", "location_count": 2, "location_summary": "Atlanta, Georgia • Seattle, Washington", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01701323" } ] }